Related Experiment Video
Updated: Nov 11, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling
Vidyasiri Vemulapalli1,2, Lily A Chylek3, Alison Erickson4
1Department of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, United States.
Abstract:
SHP2 is a protein tyrosine phosphatase that normally potentiates intracellular signaling by growth factors, antigen receptors, and some cytokines, yet is frequently mutated in human cancer. Here, we examine the role of SHP2 in the responses of breast cancer cells to EGF by monitoring phosphoproteome dynamics when SHP2 is allosterically inhibited by SHP099. The dynamics of phosphotyrosine abundance at more than 400 tyrosine residues reveal six distinct response signatures following SHP099 treatment and washout. Remarkably, in addition to newly identified substrate sites on proteins such as occludin, ARHGAP35, and PLCγ2, another class of sites shows reduced phosphotyrosine abundance upon SHP2 inhibition. Sites of decreased phospho-abundance are enriched on proteins with two nearby phosphotyrosine residues, which can be directly protected from dephosphorylation by the paired SH2 domains of SHP2 itself. These findings highlight the distinct roles of the scaffolding and catalytic activities of SHP2 in effecting a transmembrane signaling response.
Insights
SHP2 protein tyrosine phosphatase is crucial for cancer cell signaling. Inhibiting SHP2 reveals new substrate sites and its dual role in regulating cell responses to growth factors like EGF.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- SHP2 (a protein tyrosine phosphatase) regulates intracellular signaling pathways.
- Mutations in SHP2 are common in human cancers, affecting cell growth.
- SHP2's role in breast cancer and response to EGF requires further elucidation.
Purpose of the Study:
- To investigate the function of SHP2 in breast cancer cells.
- To analyze phosphoproteome dynamics upon SHP2 inhibition using SHP099.
- To identify novel SHP2 substrates and understand its regulatory mechanisms.
Main Methods:
- Allosteric inhibition of SHP2 using the compound SHP099.
- Monitoring phosphoproteome dynamics in breast cancer cells.
- Quantitative analysis of phosphotyrosine abundance changes.
Main Results:
- Six distinct phosphotyrosine abundance response signatures were identified.
- New SHP2 substrate sites were discovered on proteins including occludin, ARHGAP35, and PLCγ2.
- SHP2 inhibition decreased phosphotyrosine abundance at specific sites, particularly those with paired phosphotyrosine residues.
Conclusions:
- SHP2 plays a complex role in transmembrane signaling.
- SHP2's scaffolding and catalytic activities differentially regulate signaling responses.
- Understanding SHP2's function is critical for developing targeted cancer therapies.
Related Concept Videos
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
cAMP-dependent Protein Kinase Pathways

